These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 21226636)

  • 1. Improving adherence in osteoporosis: a new management algorithm for the patient with osteoporosis.
    Baio G; Barbagallo M; D'Avola G; Di Luccio A; Di Tanna GL; Falaschi P; Iolascon G; Malavolta N; Robbiati F; Ulivieri FM
    Expert Opin Pharmacother; 2011 Feb; 12(2):257-68. PubMed ID: 21226636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.
    Cole RE
    Postgrad Med; 2011 Mar; 123(2):131-44. PubMed ID: 21474901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Twice-a-month" clodronate 200 mg IM: a new dosing regimen and improved therapy adherence in the treatment of postmenopausal osteoporosis.
    Muratore M; Quarta L; Calcagnile F; Quarta E
    Adv Ther; 2010 May; 27(5):314-20. PubMed ID: 20526703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
    Cosman F; Borges JL; Curiel MD
    Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland.
    Hiligsmann M; McGowan B; Bennett K; Barry M; Reginster JY
    Value Health; 2012; 15(5):604-12. PubMed ID: 22867768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy.
    Gold DT; Alexander IM; Ettinger MP
    Ann Pharmacother; 2006 Jun; 40(6):1143-50. PubMed ID: 16735667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
    Josse R; Khan A; Ngui D; Shapiro M
    Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving compliance and persistence with bisphosphonate therapy for osteoporosis.
    Emkey RD; Ettinger M
    Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
    McHorney CA; Schousboe JT; Cline RR; Weiss TW
    Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem.
    Cramer JA; Silverman S
    Am J Med; 2006 Apr; 119(4 Suppl 1):S12-7. PubMed ID: 16563936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
    Rosa J; Vanuga P; Payer J; Svobodník A
    Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance.
    Boonen S; Vanderschueren D; Venken K; Milisen K; Delforge M; Haentjens P
    J Intern Med; 2008 Oct; 264(4):315-32. PubMed ID: 18823505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
    Miller PD
    Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimising bisphosphonate treatment outcomes in postmenopausal osteoporosis: review and Italian experience.
    Rossini M; Di Munno O; Gatti D; Giannini S; Minisola S; Varenna M; Adami S
    Clin Exp Rheumatol; 2011; 29(4):728-35. PubMed ID: 21813068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of bisphosphonates in the management of postmenopausal osteoporosis.
    Papapoulos SE
    Ann N Y Acad Sci; 2011 Feb; 1218():15-32. PubMed ID: 20946579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of the cost effectiveness of bisphosphonates in the treatment of post-menopausal osteoporosis in Switzerland.
    Lippuner K; Pollock RF; Smith-Palmer J; Meury T; Valentine WJ
    Appl Health Econ Health Policy; 2011 Nov; 9(6):403-17. PubMed ID: 21910511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent developments in bisphosphonate therapy.
    Silverman SL; Maricic M
    Semin Arthritis Rheum; 2007 Aug; 37(1):1-12. PubMed ID: 17303219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming problems with adherence to osteoporosis medication.
    Rabenda V; Reginster JY
    Expert Rev Pharmacoecon Outcomes Res; 2010 Dec; 10(6):677-89. PubMed ID: 21155701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.